Abstract
Background: Previous reports showed lack of consensus on the possible etiology of coronary artery disease (CAD) between HIV-treatment with highly active antiretroviral therapy (HAART) and HIV-infection in particular. The aim of this study was to find out correlations of HIV-treatment and HIV-infection with CAD risk.
Method: One hundred and twenty (120) participants involving HIV-patients on treatment (n = 40), treatment-naïve (n =40) and equal number of age- and sex-matched controls were enrolled. The total cholesterol, triglycerides and lipoprotein (HDL-C) were analyzed using spectrophotometry. The LDL-C was calculated using Friedewald equation, TC/HDL-C and LDL-C/HDL-C ratios were also calculated. The CD4+ cell count was determined using flow cytometry.
Result: The mean plasma total cholesterol levels in patients’ groups on treatment and treatment-naïve were significantly reduced when compared with controls, but the mean triglyceride levels for both treatment and the treatment-naïve groups were significantly increased when compared with controls. However, HDL-C and LDL-C values for patients on HAART and the treatment-naive were significantly reduced when compared with controls respectively. The CAD risk predictors, LDL-c and TC/HDL-C ratio, were significantly increased in patients on HAART when compared with the treatment-naive.
The mean CD4+ cell count in treatment-naive was significantly lowered against both groups for treatment and controls.
Conclusion: In this present study, abnormal lipid profile was associated with both HIV-infection and HAART-treatment.
However, TC/HDL-C ratio, the strong predictor of CAD events in metabolic disorder was markedly high in HAARTtreatment and the associated difference may threaten higher risk for cardiovascular disease (CVD) during treatment.
Keywords: Coronary Artery Disease; Dyslipidemia; Highly Active Antiretroviral Therapy; Human Immunodeficiency
Virus.
Kamoru Ademola, A., M, O , D, A , A, A , A, M , A, O , A, O , A, A , I, U & A, O (2018). CD4+ Cell Count, Lipid and Lipoprotein Levels in HIV Patients on Drug Treatment. Afribary. Retrieved from https://tracking.afribary.com/works/cd4-cell-count-lipid-and-lipoprotein-levels-in-hiv-patients-on-drug-treatment
Kamoru Ademola, Adedokun, et. al. "CD4+ Cell Count, Lipid and Lipoprotein Levels in HIV Patients on Drug Treatment" Afribary. Afribary, 26 Mar. 2018, https://tracking.afribary.com/works/cd4-cell-count-lipid-and-lipoprotein-levels-in-hiv-patients-on-drug-treatment. Accessed 23 Nov. 2024.
Kamoru Ademola, Adedokun, Olisekodiaka M , Adeyeye D , Adepeju A , Muhibi A , Onifade A , Olaoye A , Adetoro A , UGWU I and Oyenike A . "CD4+ Cell Count, Lipid and Lipoprotein Levels in HIV Patients on Drug Treatment". Afribary, Afribary, 26 Mar. 2018. Web. 23 Nov. 2024. < https://tracking.afribary.com/works/cd4-cell-count-lipid-and-lipoprotein-levels-in-hiv-patients-on-drug-treatment >.
Kamoru Ademola, Adedokun, Olisekodiaka M , Adeyeye D , Adepeju A , Muhibi A , Onifade A , Olaoye A , Adetoro A , UGWU I and Oyenike A . "CD4+ Cell Count, Lipid and Lipoprotein Levels in HIV Patients on Drug Treatment" Afribary (2018). Accessed November 23, 2024. https://tracking.afribary.com/works/cd4-cell-count-lipid-and-lipoprotein-levels-in-hiv-patients-on-drug-treatment